Matthew Mason, UK General Manager, ViroPharma, explains why they decided to join the ABPI:
"Our goal at ViroPharma is to improve the lives of patients and to deliver medicines that address serious unmet medical needs, and I firmly believe that the ABPI will be able to help us to achieve that goal."
Stephen Whitehead, Chief Executive of the ABPI, welcomed ViroPharma’s decision:
"I’m delighted ViroPharma has joined the ABPI. The ABPI has fundamentally changed in recent years to better reflect our modern industry, and I’m pleased that these changes and the benefits which we provide to our members have been recognised by ViroPharma. This is a crucial time for industry and it is essential that we ensure innovative companies like ViroPharma are encouraged to keep investing in the UK."
ViroPharma focus on providing products to physician specialists that support patients with serious diseases for which there is an unmet medical need, including hereditary angioedema, Clostridium difficile infection, adrenal insufficiency and prolonged, acute, convulsive seizures in children and adolescents.
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
Notes to editor
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.